Growing Awareness And Advances In Skin Cancer Care Drive Market Growth: A Significant Driver Propelling The Cutaneous Squamous Cell Carcinoma (CSCC) Market In 2025

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Cutaneous Squamous Cell Carcinoma (CSCC) Market Size and Projected Growth Rate?
In recent years, there has been significant growth in the cutaneous squamous cell carcinoma (cSCC) market size. The market is expected to expand from $7.45 billion in 2024 to reach $7.90 billion by 2025, representing a compound annual growth rate (CAGR) of 6.1%. This uptrend during the historical period is linked to factors such as increased instances of non-melanoma skin cancers, an aging population, heightened exposure to ultraviolet rays, advancements in healthcare facilities, and the growing deployment of immunotherapy in oncology treatments.

The market for cutaneous squamous cell carcinoma (cSCC) is projected to experience significant expansion in the approaching years, reaching an estimate of $9.90 billion in 2029, with a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this growth during the predicted period include the improved accessibility of targeted therapies, a growing consciousness about skin cancer prevention, the expansion of medical tourism specific to cancer treatments, the rising trend of adopting minimally invasive surgeries, and positive government policies towards cancer care. The forecast period will likely see dominant trends such as improvements in dermatology diagnostics, the evolution of advanced radiotherapy techniques, incorporation of technology in dermatology, novel developments in immunotherapy treatments, and progress in photodynamic therapy.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21163

What Are the Major Segments in the Cutaneous Squamous Cell Carcinoma (CSCC) Market?
The cutaneous squamous cell carcinoma (CSCC) market covered in this report is segmented -

1) By Treatment: Surgical Treatment, Non-Surgical Treatment
2) By Diagnosis: Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Biopsy
3) By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Other Applications

Subsegments:
1) By Surgical Treatment: Excisional Surgery, Mohs Micrographic Surgery, Curettage And Electrodessication
2) By Non-Surgical Treatment: Radiation Therapy, Cryotherapy, Photodynamic Therapy, Topical Therapies, Systemic Therapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21163&type=smp

What Are The Driving Cutaneous Squamous Cell Carcinoma (CSCC) Market Evolution?
The surge in knowledge about skin cancer is expected to boost the expansion of the cutaneous squamous cell carcinoma (cSCC) market in the future. Skin cancer develops from an atypical growth of skin cells, often instigated by ere*xposure to UV radiation, and can vary from harmless to threatening to life. This heightened awareness about skin cancer can be attributed to extensive campaigns promoting public health, improved access to vital information, and a growing focus on early identification and prevention, which results in an increased need for diagnosis and treatment options. Cutaneous squamous cell carcinoma (cSCC) holds potential for pushing forward care for skin cancer by enabling precise therapies, refining diagnoses, and improving patient results, hence encouraging superior management of the disease. For instance, in January 2024, as reported by the American Cancer Society - a US-based non-profit organization committed to the eradication of cancer - there were 104,930 skin cancer cases identified in 2023, which shows a 3.2% rise from the 108,270 cases reported in 2022. Consequently, this increased understanding about skin cancer is expected to drive growth in the cutaneous squamous cell carcinoma (cSCC) market.

Which Firms Dominate The Cutaneous Squamous Cell Carcinoma (CSCC) Market Segments?
Major companies operating in the cutaneous squamous cell carcinoma (CSCC) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, 3M Company, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Hikma Pharmaceuticals plc, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., CureVac N.V., Vidac Pharma Inc.

What Cutaneous Squamous Cell Carcinoma (CSCC) Market Trends Are Gaining Traction Across Different Segments?
Leading corporations within the cutaneous squamous cell carcinoma (cSCC) market are concentrating their efforts on enhancing immuno-oncology treatments such as PD-L1 inhibitors and targeted therapies, with the aim of offering superior patient outcomes and competent solutions for treating severe skin cancer. PD-L1, the protein which depresses the immune response by connecting to PD-1 receptors on T-cells, assists in the concealment of cancer cells from the immune system. For instance, Checkpoint Therapeutics Inc., an American biotech firm, gained FDA approval for its drug, Unloxcyt (cosibelimab-ipdl), in December 2024. The drug's unique capability to inhibit PD-L1 boosts the immune system's capacity to counter cancer and presents a safer and more effective treatment alternative. Its combined methods of action also furnish an encouraging strategy for handling advanced cSCC. The clearance was granted on the basis of the results from the CK-301-101 clinical trial, revealing significant objective response rates and sustained responses among patients with advanced cSCC.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/cutaneous-squamous-cell-carcinoma-cscc-global-market-report

Which Is The Largest Region In The Cutaneous Squamous Cell Carcinoma (CSCC) Market?
North America was the largest region in the cutaneous squamous cell carcinoma (CSCC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cutaneous squamous cell carcinoma (CSCC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Cutaneous Squamous Cell Carcinoma (CSCC) Market?
2. What is the CAGR expected in the Cutaneous Squamous Cell Carcinoma (CSCC) Market?
3. What Are the Key Innovations Transforming the Cutaneous Squamous Cell Carcinoma (CSCC) Industry?
4. Which Region Is Leading the Cutaneous Squamous Cell Carcinoma (CSCC) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.